Silence Therapeutics Plc - American Depository Share - Çeyreklik Finansal İstatistikler (NASDAQ:SLN)

Financials

İşletme faaliyetlerinden elde edilen nakit -27.48 M-12.31 M-21.78 M-10.89 M-17.29 M-15.6 M -65.56 M Yatırım faaliyetlerinden elde edilen nakit 66.13 M-44.38 M-1.56 M51.29 M-53.34 M10 M 6.39 M Finansman faaliyetlerinden elde edilen nakit -98 K14 K1 000000 1 000 Serbest nakit akışı -27.48 M-12.31 M-21.78 M-10.89 M-17.29 M-15.6 M -65.56 M

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

SLN

Financials

Silence Therapeutics Plc - American Depository Share

Haberler

Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?

Silence Therapeutics kazancı $0,11 ile beklentilere göre daha iyi, kâr ise beklentilere göre düşük

Silence Therapeutics earnings beat by $0.11, revenue fell short of estimates

Jefferies, Silence Therapeutics hissesi için Al tavsiyesini yineledi

Jefferies reiterates Buy on Silence Therapeutics stock ahead of data

Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?

William Blair, Silence Therapeutics hissesi için tavsiyesini korudu

William Blair reiterates Silence Therapeutics stock rating on divesiran potential

H.C. Wainwright, Silence Therapeutics hissesi için Al tavsiyesini 75 dolar hedefle yineledi

H.C. Wainwright reiterates Buy rating on Silence Therapeutics stock at $75

Silence Therapeutics CFO Rhonda Hellums yönetim kuruluna atandı

TreeFrog Therapeutics Mark Rothera’yı yeni CEO olarak atadı